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Introduction
The prevalence of atrial fibrillation (AF) and AF-related adverse events is growing worldwide along with the rise in the elderly population. In fact AF is the most common arrhythmia seen in our practice [1] . Clinically we subdivide AF into 2 main categories including valvular and non-valvular AF, Hasan Kaya et al., Valvular atrial fibrillation which are associated with a 17 and 5 fold increased risk of stroke per annum, respectively [1, 2] . Thromboembolism is the leading cause of AF-related adverse events, but it is valvular AF that is associated with the highest risk of stroke. Even so, most studies investigating AF and stroke have been mostly performed with non-valvular AF patients. This has led to a paucity of detailed epidemiological information regarding risk factors for thromboembolism in patients with valvular AF [3] [4] [5] [6] [7] [8] [9] [10] . Although there was a multicenter study that investigated the epidemiology of heart valve diseases in Turkey, this study did not focus on valvular AF patients [11] . To our knowledge the Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) multicenter cohort study was the first that strived to close the gap in knowledge pertaining to the demographic characteristics, attainment of therapeutic international normalized ratio (INR), and risk of thromboembolism in patients with valvular AF.
Methods

Study design and patient selection
AFTER is a prospective, multicenter cohort study that was designed with the aim to describe the epidemiology of AF in Turkey [12] . A total of 2,242 patients were recruited from 17 hospitals so to have representation from the populations characteristic of the 7 geographical regions of Turkey. This recruitment period took place during the period from April 2012 to December 2012 for a total duration of about 9 months.
The inclusion criteria were the following: "all consecutive patients over 18 years of age who presented to cardiology outpatient clinics with at least one attack of AF identified on electrocardiographic examination". Patients that refused to participate in the study or sign the consent form were excluded. A licensed cardiologist obtained, recorded and evaluated patient basic demographic data and medications. Every patient was required to sign an informed consent document and complete a standard registration form. The AFTER study was approved by the Ethics Committee.
Descriptions
Types of AF were defined according to the European Society of Cardiology (ESC) guidelines [1] . Valvular AF was defined as a patient presenting with AF and rheumatic mitral valve stenosis or prosthetic heart valve(s) [1, 2] . Paroxysmal AF was defined as self-terminating and usually lasting from 48 h to 7 days. Persistent AF was considered an episode of AF that either lasts longer than 7 days or requires termination by cardioversion. Permanent AF was described as AF that occurs on 2 occasions within at least 6 months separating each episode with no evidence of sinus rhythm in between.
All patients received routine electrocardiographic and echocardiographic examination. Hypertension was defined as a blood pressure measurement greater than 140/90 mm Hg, a prior diagnosis of hypertension or requiring antihypertensive medication. Diabetes mellitus was designated as a fasting blood glucose level greater than 126 mg, a prior diagnosis of diabetes or being on anti--diabetic therapy. Vascular disease was described as having a previous myocardial infarction, a complex aortic plaque or peripheral artery disease.
Therapeutic INR range was defined as 2.0-3.0 in patients with rheumatic mitral valve stenosis and aortic prosthetic valves. For patients with prosthetic mitral valves or both aortic and mitral prosthetic valves, the therapeutic INR range was 2.5-3.5 [13] . Labile INR was considered attaining therapeutic range less than 60% of the time [14] .
Statistical analysis
Statistical Package for Social Sciences software (SPSS 12, Chicago, IL, USA) was used for data analysis. Normality analyses were assessed using Kolmogorov-Smirnov and Shapiro-Wilk tests. Descriptive parameters were shown as the mean ± one standard deviation or in percentages. For quantitative data comparison, normally distributed parameters were compared using Student's t-test. Parameters that did not follow a normal distribution were compared using the Mann-Whitney U test. The c 2 test was used for the comparison of qualitative data. A multivariate logistic regression analysis was performed to evaluate the independent predictors of thromboembolic events using age, gender, hypertension, heart failure, vascular disease and diabetes mellitus as potential covariates. A p-value lower than 0.05 was considered significant.
Results
The entire patient cohort with AF numbered to 2,242, and after removing patients with non-valvular AF the final cohort consisted of 497 patients with valvular AF. There were 217 patients with rheumatic mitral valve stenosis and 280 patients had prosthetic heart valves. Among patients with prosthetic valves, 207 (73.9%) of them had mitral valve replacement (MVR), 49 (17.5%) had aortic valve replacement (AVR) and 24 (8.6%) had both MVR and AVR. Valvular AF patient demographics are detailed in When comparisons were made between patients with mitral stenosis vs. those who had prosthetic valves, heart failure was more common in patients with prosthetic valves ( Figure 1 .
Echocardiographic examinations showed that a lower ejection fraction was more common in patients with prosthetic valves. However, spontaneous echo contrast or thrombus visualization in the left atrium was more commonly observed in patients with rheumatic mitral valve stenosis. The average left atrial diameters were similar between both study groups.
Multivariate analysis demonstrated that age was the only independent predictor of thromboembolic events (odds ratio 1.034, 95% confidence interval 1.009-1.059, p = 0.007). Specifically, each year of aging was associated with a 3.4% increase in thromboembolic event risk (Table 3) .
Discussion
Research in AF has been mostly conducted in Western countries, and almost all of these studies only involved non-valvular AF patients. Several countries that have measured the incidence of valvular AF include the United States at 6%, Japan at 14% and the AFNET study demonstrated a 9% incidence in Germany [5, 7, 15] . In a previous study performed in Turkey it was found that valvular AF has a frequency of 22%, which likely reflects the higher rates of rheumatic heart disease in Turkey as compared to other developed nations [3] . In a different Turkish multicenter study performed with 1,300 patients it was determined that 11% had mitral valve stenosis and 13% had prosthetic valves [11] . Furthermore, AF was detected in 28% of patients with valvular disease, and of patients with both AF and valvular disease 38% had mitral stenosis. By investigating valvular AF in Turkey, we hope to inform the international community about its etiology, prevalence, treatment, and the risk factors associated with thromboembolism.
According to our findings, one-fifth of AF cases were valvular in origin. Rheumatic valvular disease made up a slight majority of these cases at 56% while prosthetic valves made up the difference at 44%. Of note, MVR were the most common prosthetic heart valves. In fact, valvular AF occurred more frequently in females, which may be a reflection of the greater likelihood of women having mitral stenosis as compared to men. Additionally, most patients exhibited permanent AF, and the most common comorbid condition was hypertension in valvular AF patients.
However, one of the most compelling findings in our study was poor INR achievement among valvular AF patients. Upon analyzing the entire cohort in terms of warfarin use, 83.1% of patients were taking this anticoagulant. Nevertheless, only 36.1% of those patients demonstrated a therapeutic INR level. Unfortunately, it was not possible to compare our data with other studies, because our literature search yielded no papers regarding warfarin use and the attainment of effective INR for patients with valvular AF.
Subgroup analysis revealed that the highest rate of warfarin use was detected in patients with both MVR and AVR. Conversely, patients with rheumatic mitral valve stenosis had the lowest rate of warfarin use. To distinguish between therapeutic and suboptimal INRs we adopted the American College of Chest Physicians (ACCP) recommendations, because they define INR limits based on Because patients with valvular AF may be at risk of thromboembolic events due to having sub--therapeutic INRs, we strived to find a means to lower the risk of stroke in these patients. There are 2 standardized measures to identify stroke risk in non-valvular AF that include the CHADSVASC and CHADS scores, but no such score exists for valvular AF [17, 18] . Thus we performed a regression analysis using CHADSVASC score parameters. Only age was detected as an independent predictor of thromboembolic events in patients with valvular AF. Specifically, with every year of aging there is a 3.4% increased risk of thromboembolism in these patients.
Limitations of the study
INR values were not measured at a central laboratory. The analysis was based on a cross--sectional survey and the prospective data will be gathered in the future.
Conclusions
According to the AFTER study, approximately 20% of AF cases in Turkey were of valvular origin. Even though 83.1% of these patients were using warfarin, only one-third of them achieved a therapeutic INR level. Age was the only independent predictor of stroke in this patient group. These results suggest that the clinical management for anticoagulation in these patients is currently sub--optimal. Also more research must be done to determine what risk factors predispose valvular AF patients to stroke. This way, practice guidelines specifically tailored to patients with valvular AF may be formulated so that improvements can be made in their clinical management.
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